The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature
Abstract
There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (1) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series. We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa‐induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD‐onset well before levodopa availability (pre‐levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series. Among series containing pre‐levodopa era patients, the median dyskinesia frequency was already 50% by 5–6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4–6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing‐off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4–6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures. The conclusions reached were: (1) patients from the pre‐levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre‐existing PD; (2) in the present era, patients treated with levodopa therapy for 4–6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less. © 2001 Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Treatment of Parkinsonism With Levodopa
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 604
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Young onset Parkinson's disease
Quinn, N., Critchley, P., & Marsden, C. D. (1987) · Movement Disorders · doi:10.1002/mds.870020201 · Cited by 443
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
Barbeau, A. (1969) · PubMed · Cited by 410
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality
Schrag, A., Ben‐Shlomo, Y., Brown, R., David Marsden, C., & Quinn, N. (1998) · Movement Disorders · doi:10.1002/mds.870130605 · Cited by 311
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease
Block, G., Liss, C., Reines, S., Irr, J., & Nibbelink, D. (1997) · European Neurology · doi:10.1159/000117399 · Cited by 234
An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
Olanow, C. W., & Koller, W. C. (1998) · Neurology · doi:10.1212/wnl.50.3_suppl_3.s1 · Cited by 203
Young‐onset Parkinson's disease: A clinical review
Golbe, L. I. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.168 · Cited by 200
Koller, W. C., Hutton, J. T., Tolosa, E., Capilldeo, R., & the Carbidopa/Levodopa Study Group (1999) · Neurology · doi:10.1212/wnl.53.5.1012 · Cited by 200
Montastruc, J. L., Rascol, O., Senard, J. M., & Rascol, A. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1034 · Cited by 198
Rascol, O., Brooks, D. J., Brunt, E. R., Korczyn, A. D., Poewe, W. H., & Stocchi, F. (1998) · Movement Disorders · doi:10.1002/mds.870130111 · Cited by 186
Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa)
MCDOWELL, F., LEE, J. E., SWIFT, T., SWEET, R. D., OGSBURY, J. S., & KESSLER, J. T. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-72-1-29 · Cited by 183
SWEET, R. D., & McDOWELL, F. H. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-456 · Cited by 172
Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease
Rinne, U. K. (1987) · Neurology · doi:10.1212/wnl.37.5.826 · Cited by 166
The Impact of Treatment with Levodopa on Parkinson's Disease
(1980) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067623 · Cited by 164
Low‐dose L‐dopa therapy in Parkinson's disease: A 6‐year follow‐up study
Poewe, W. H., Lees, A. J., & Stern, G. M. (1986) · Neurology · doi:10.1212/wnl.36.11.1528 · Cited by 163
On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
Nutt, J. G. (1987) · Annals of Neurology · doi:10.1002/ana.410220415 · Cited by 159
(1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-157_5 · Cited by 148
Cabergoline in the treatment of early parkinson's disease
Rinne, U. K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O. S., Martí-Massó, J. F., Montastruc, J., MARSDEN, C. D., Dubini, A., Orlando, N., et al. (1997) · Neurology · doi:10.1212/wnl.48.2.363 · Cited by 130
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
Rinne, U. K. (1989) · Neurology · doi:10.1212/wnl.39.3.336 · Cited by 127
Combined bromocriptine‐levodopa therapy early in Parkinson's disease
Rinne, U. K. (1985) · Neurology · doi:10.1212/wnl.35.8.1196 · Cited by 109
Dupont, E., Andersen, A., Boas, J., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb00163.x · Cited by 108
Cedarbaum, J. M., Gandy, S., & MCDOWELL, F. H. (1991) · Neurology · doi:10.1212/wnl.41.5.622 · Cited by 108
Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism
Mones, R. J., Elizan, T. S., & Siegel, G. J. (1971) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.34.6.668 · Cited by 106
Does selegiline modify the progression of early Parkinson's disease? Results from a five‐year study
Larsen, J. O., Boas, J., Erdal, J. E., & Norwegian‐Danish Study Group (1999) · European Journal of Neurology · doi:10.1046/j.1468-1331.1999.650539.x · Cited by 106
L-DOPA IN IDIOPATHIC PARKINSONISM
Calne, D. B. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90536-4 · Cited by 101
CARACENI, T., Scigliano, G., & Musicco, M. (1991) · Neurology · doi:10.1212/wnl.41.3.380 · Cited by 84
L-Dopa in Parkinson's Syndrome
(1969) · New England Journal of Medicine · doi:10.1056/nejm196907312810517 · Cited by 74
Treatment of Parkinsonism with Laevo-Dopa
Mawdsley, C. (1970) · BMJ · doi:10.1136/bmj.1.5692.331 · Cited by 73
TREATMENT OF PARKINSON'S DISEASE WITH AMANTADINE AND LEVODOPA
Parkes, J. D., Curzon, G., Knott, P. J., et al. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91834-4 · Cited by 69
Pathophysiology of L-dopa-induced dyskinesias.
Bédard, P. J., Blanchet, P. J., Lévesque, D., Soghomonian, J., Grondin, R., Morissette, M., Goulet, M., Calon, F., Falardeau, P., Gomez‐Mancilla, B., et al. (1999) · PubMed · Cited by 63
Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years
Reardon, K. A., Shiff, M., & Kempster, P. A. (1999) · Movement Disorders · Cited by 41
Lacunae and Cribriform Cavities of the Brain
Mancardi, G., Romagnoli, P., Tassinari, T., Gandolfo, C., Primavera, A., & Loeb, C. (2008) · European Neurology · doi:10.1159/000116220 · Cited by 37
Kurebayashi, J., Otsuki, T., Yamamoto, S., Kurosumi, M., Nakata, T., Akinaga, S., & Sonoo, H. (1998) · Oncology · doi:10.1159/000055256 · Cited by 33
Treatment of Parkinson's disease with l-DOPA and decarboxylase inhibitor
Rinne, U. K., Sonninen, V. H., & Siirtola, T. (1972) · Journal of Neurology · doi:10.1007/bf00316422 · Cited by 32
Treatment of Parkinsonism with Levodopa
Lee, J. E., SWEET, R. D., & MCDOWELL, F. H. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-75-5-703 · Cited by 23
Rinne, U. K., Birket-Smith, E., Dupont, E., et al. (1975) · Journal of Neurology · doi:10.1007/bf00312459 · Cited by 23
Levodopa-induced dyskinesia: clinical observations
Friedman, A. (1985) · Journal of Neurology · doi:10.1007/bf00314037 · Cited by 18
Mesulergine in early Parkinson's disease: a double blind controlled trial.
Dupont, E., Mikkelsen, B. O., & Jakobsen, J. C. (1986) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.4.390 · Cited by 8
Cited by
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Metadata
- Authors
- Ahlskog, J. E., & Muenter, M. D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 16
- Issue
- 3
- Pages
- 448-458
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2115222037
- Cited by
- 1,454
- References
- 47
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.